Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
American Journal of Cardiovascular Drugs
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-11
DOI
10.1007/s40256-020-00409-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
- (2020) Bianca Rocca et al. BLOOD
- Population health bio-phenotypes in 11–12 year old children and their midlife parents: Growing Up in Australia’s Child Health CheckPoint
- (2019) Melissa Wake et al. BMJ Open
- Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. Primary Care Diabetes
- Platelet function testing: dead or alive
- (2018) C. Helten et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes
- (2018) Paul Harrison et al. PLATELETS
- Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease
- (2018) Liv Vernstrøm et al. THROMBOSIS RESEARCH
- Influence of pre-analytical time and temperature conditions on serum thromboxane B 2 levels
- (2018) J.J.K. van Diemen et al. THROMBOSIS RESEARCH
- The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
- (2018) J Michael Gaziano et al. LANCET
- Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Once versus twice daily aspirin after coronary bypass surgery: a randomized trial
- (2017) J. S. Paikin et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
- (2017) Torbjörn Ivert et al. THROMBOSIS RESEARCH
- Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease
- (2017) Sanne Bøjet Larsen et al. Journal of the American Heart Association
- The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
- (2016) D Bem et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement
- (2016) Giovanna Petrucci et al. THROMBOSIS AND HAEMOSTASIS
- Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients
- (2016) Kazuyuki Nagatsuka et al. THROMBOSIS AND HAEMOSTASIS
- Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes
- (2015) M. A. Bethel et al. DIABETIC MEDICINE
- Aspirin response: Differences in serum thromboxane B2 levels between clinical studies
- (2015) Charlotte Brun et al. PLATELETS
- Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
- (2015) Susanne Gruber et al. THROMBOSIS AND HAEMOSTASIS
- Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: The example of NOACs in atrial fibrillation
- (2014) Daniel Caldeira et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes
- (2014) Kristian H. Christensen et al. PLATELETS
- Prevalence of High On-treatment Platelet Reactivity in Diabetic Patients Treated with Aspirin
- (2013) Scot H. Simpson et al. AMERICAN JOURNAL OF MEDICINE
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
- (2013) Udaya S. Tantry et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- High on-treatment platelet reactivity – definition and measurement
- (2013) Marco Cattaneo THROMBOSIS AND HAEMOSTASIS
- Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease
- (2012) Jean-Guillaume Dillinger et al. AMERICAN HEART JOURNAL
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
- (2012) B. ROCCA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Functional testing methods for the antiplatelet effects of aspirin
- (2011) Karsten Schrör et al. Biomarkers in Medicine
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
- (2011) Davide Capodanno et al. Circulation-Cardiovascular Interventions
- Exploring Mechanisms of Graft Occlusion
- (2011) Robert F. Storey JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
- (2010) E. L. GROVE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
- (2010) Adeline Vermillet et al. THROMBOSIS AND HAEMOSTASIS
- Why an aspirin a day no longer keeps the doctor away …
- (2010) Marie Lordkipanidzé THROMBOSIS AND HAEMOSTASIS
- The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
- (2009) A. Dragani et al. BLOOD
- Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization
- (2009) Andrew L. Frelinger et al. CIRCULATION
- Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays
- (2009) Francesca Santilli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Aspirin, 110 years later
- (2009) C. PATRONO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Protein synthesis by platelets: historical and new perspectives
- (2009) A. S. WEYRICH et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery
- (2008) Frantisek Bednar et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started